retatrutide release date usa FDA Approval Status 2026: Everything We Know So Far Retatrutide UK 2026: Phase 3

Originally prescribed to treat diabetes, GLP-1s have been shown to help with a range of chronic conditions, including heart disease and obesity

The close integration between oxidative, electrophilic, ER, and inflammation stress is now regarded as the basis for many chronic diseases (177) and, increasingly, for chronic pancreatitis (97, 112, 123)

What many users experience and misinterpret as tolerance represents the natural endpoint of weight loss

Furthermore, upregulation of voltage-gated Ca 2+ channels (VGCCs), particularly CaV1.3, promotes resistance to androgen deprivation therapy (ADT) and the progression of castration-resistant prostate cancer (CRPC) [32]

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, meaning it mimics a hormone naturally produced in your gut